Hansoh Pharmaceutical (03692): NDA for Damaletinib Mesylate Tablets Accepted by China's NMPA

Hansoh Pharma (03692) announced that on February 27, 2026, the marketing authorization application (NDA) for the group's innovative drug, Dacemetinib Mesylate Tablets, in combination with Aumolertinib Mesylate Tablets (Ameile®), was accepted by the National Medical Products Administration (NMPA) of China. This combination is intended for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who are positive for epidermal growth factor receptor (EGFR) gene mutations and have failed treatment with EGFR tyrosine kinase inhibitors (TKIs), accompanied by mesenchymal-epithelial transition factor (MET) amplification. Dacemetinib Mesylate Tablets (HS-10241) is an orally administered, highly selective c-MET TKI independently developed by the group.